Look for a new Sanofi CEO by March, says chairman, as earnings top forecast

Tracy Staton Striking out in our CEO search? Not us, says Sanofi. Chairman Serge Weinberg says the board is talking to a "limited number of candidates" and expects to make ...

Sanofi’s finally going to name a new CEO, chairman says

Damian Garde Sanofi will announce its new chief executive by the end of March, the drugmaker's chairman said, ending months of speculation and reported recruitment failure. FierceBiotech ...

AstraZeneca continues its respiratory land grab with $600M-plus Actavis deal

Carly Helfand AstraZeneca CEO Pascal Soriot has said he wants to dominate in the respiratory field. Actavis CEO Brent Saunders has no such ambitions. Now, the two have struck a deal. FiercePharma ...

Cost-cutting, check. Now, it’s on to dealmaking, Teva chief says

Carly Helfand Teva is ready to make some deals now. It's a mantra that's seen quite a bit of play since CEO Erez Vigodman took up the reins at the generics giant early last ...

Roche’s Parkinson’s failure a blow to researchers; Nexvet pulls off a $40M IPO;

Alok Saboo FierceBiotech News

Big shot investor plans £100M EU biotech fund, Genmab up on PhII data, J&J inks U.K. RA deal

Nick Paul Taylor In this week's EuroBiotech Report, after years of relying heavily on Neil Woodford's checkbook, early-stage British and European biotechs could soon have another ...

Strong earnings suggest Allergan sold too cheap, analyst says

Carly Helfand Allergan's fourth-quarter and full-year financials are out, and the way Bernstein analyst Ronny Gal sees it, based on the company's performance, it "should ...

Valeant is kicking tires at Salix, but a rival Shire bid could quash the idea

Carly Helfand FiercePharma News

Medicines Co. snaps up an Atlas seedling and a promising anesthetic

Damian Garde The Medicines Company bought out the shares of Annovation Biopharma it didn't already own, getting exclusive rights to a new anesthetic and scooping up a tiny biotech ...

New Zohydro formula gets FDA’s blessing, but abuse-deterrent label has to wait

Carly Helfand Since its FDA approval, the all-hydrocodone painkiller Zohydro has sparked outrage from officials and advocates trying to fight the tsunami of opioid addiction. But with ...

Esperion gets out from under the FDA and speeds toward Phase III

Damian Garde Ann Arbor, MI, biotech Esperion Therapeutics finally resolved the FDA snag standing in the way of its ambitious plans for a new cholesterol drug, clearing the company to ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS